AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03059381
Drug: Fycompa
RxNorm normalized name: FYCOMPA
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
Trial: NCT00741884
Drug: Varenicline Controlled Release 1.2 mg
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline CR tablet 1.2 mg BID for 7 weeks
Trial: NCT00741884
Drug: Varenicline Controlled Release 1.8 mg
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline CR tablet 1.8 mg BID for 7 weeks
Trial: NCT00741884
Drug: Varenicline Controlled Release 2.4 mg
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline CR tablet 2.4 mg BID for 7 weeks
Trial: NCT00741884
Drug: Varenicline Immediate Release 1 mg
RxNorm normalized name: varenicline 1 MG
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline IR tablet 1 mg BID for 7 weeks
Trial: NCT00423306
Drug: Darinaparsin
RxNorm normalized name: darinaparsin
DrugBank: Darinaparsin (DB06179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
Trial: NCT00003256
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04167774
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
Trial: NCT04167774
Drug: nb-Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
Trial: NCT00393679
Drug: amodiaquine-artesunate (ASAQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
Trial: NCT00393679
Drug: dihydroartemisinin-piperaquine (DHAPQ)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
Trial: NCT00393679
Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008.
Trial: NCT00820742
Drug: Macugen
RxNorm normalized name: Macugen
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
Trial: NCT01419132
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125-250 mg furosemide bid
Trial: NCT01419132
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125-250 mf furosemide bid
Trial: NCT00660894
Drug: folinate calcium
RxNorm normalized name: Folixate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00660894
Drug: tegafur-uracil
RxNorm normalized name: Tegafur-uracil
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00660894
Drug: tegafur-gimeracil-oteracil potassium
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02181556
Drug: Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease
Trial: NCT01530971
Drug: Supplemental 3LPM oxygen via canula
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parturients will receive supplemental oxygen (3LPM) via nasal canula
Trial: NCT00649064
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
Trial: NCT04259112
Drug: deep neuromuscular block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular block is defined as PTC 1-2.
Trial: NCT04259112
Drug: moderate neuromuscular block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular block is defined as TOF twitch 1-2.
Trial: NCT03010787
Drug: V565
RxNorm normalized name: Vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: single ascending dose of V565
Trial: NCT03010787
Drug: V565
RxNorm normalized name: Vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Multiple dose
Trial: NCT03010787
Drug: V565
RxNorm normalized name: Vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Open-label single dose
Trial: NCT03010787
Drug: V565
RxNorm normalized name: Vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Open-label single ascending dose
Trial: NCT02550327
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/m2
Trial: NCT02550327
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2
Trial: NCT02550327
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2
Trial: NCT02550327
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg
Trial: NCT00838201
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
Trial: NCT04348513
Drug: T3 solution for injection
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
Trial: NCT00391352
Drug: IFN-β-1a (Rebif®)
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 44 mcg Three times a week, subcutaneous injection
Trial: NCT03181828
Drug: Acetohydroxamic Acid Oral Tablet
RxNorm normalized name: acetohydroxamic acid Oral Tablet
DrugBank: Acetohydroxamic acid (DB00551)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
Trial: NCT02009410
Drug: Creon
RxNorm normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
Trial: NCT02009410
Drug: Creon 25000 matching Placebo
RxNorm normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
Trial: NCT00613028
Drug: Temo + Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
Trial: NCT00613028
Drug: VP-16 + Avastin
RxNorm normalized name: etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
Trial: NCT02693574
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02397863
Drug: Cannabidiol (Epidiolex)
RxNorm normalized name: cannabidiol Oral Solution [Epidiolex]
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
Trial: NCT02474199
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
Trial: NCT02474199
Drug: Immunosuppression (IS) Withdrawal
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS.
Trial: NCT01167062
Drug: Tamsulosin Hydrochloride OCAS 0.4 mg
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet OD for a maximum of 28 days
Trial: NCT01344447
Drug: Gadobutrol (Gadovist, BAY86-4875)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single bolus injection of approx. 0.1mmol/kg
Trial: NCT01026870
Drug: SCH 32088 mometasone furoate (MF) metered-dose inhaler
RxNorm normalized name: mometasone furoate Metered Dose Inhaler
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
Trial: NCT01489046
Drug: BMS-986001
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 100 mg, Once daily, At least 48 weeks
Trial: NCT01489046
Drug: BMS-986001
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 200 mg, Once daily, At least 48 weeks
Trial: NCT01489046
Drug: BMS-986001
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 400 mg, Once daily, At least 48 weeks
Trial: NCT01489046
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Trial: NCT01489046
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Trial: NCT01489046
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Trial: NCT02619409
Drug: Bupivacaine Only
RxNorm normalized name: Bupivacaine only product
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
Trial: NCT01714310
Drug: lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Titration and open label treatment from baseline visit for 12 week study.
Trial: NCT01225445
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg daily
Trial: NCT00994448
Drug: Bupropion SR 150mg tabs
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 150mg tabs (Zyban) twice daily
Trial: NCT02182375
Drug: BI 201335 NA
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182375
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03670810
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT04155515
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 1000mg/1200mg
Trial: NCT00004903
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004903
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004903
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004903
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02279186
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Injection
Trial: NCT00048542
Drug: OLE BSA Adalimumab +/- MTX
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
Trial: NCT00048542
Drug: OLE FD Adalimumab +/- MTX
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
Trial: NCT00118807
Drug: Amodiaquine plus artesunate (AQ/AS)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00118807
Drug: Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00118807
Drug: Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00937417
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00937417
Drug: vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02255370
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
Trial: NCT00843921
Drug: N-carbamylglutamate
RxNorm normalized name: N-Carbamylglutamate
DrugBank: Carglumic acid (DB06775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
Trial: NCT00014365
Drug: MKC-1
RxNorm normalized name: MKC-1
DrugBank: MKC-1 (DB05608)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03168464
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Trial: NCT03168464
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Trial: NCT00046735
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
Trial: NCT00403000
Drug: dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01627938
Drug: Dexrazoxane (DRZ) plus Mitoxantrone (MX)
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
Trial: NCT01627938
Drug: Placebo plus Mitoxantrone (MX)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
Trial: NCT04013620
Drug: Belatacept 250 Milligram Intravenous Powder for Solution
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Trial: NCT01448018
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 monthly intravitreous injection as soon as possible after the inclusion
Trial: NCT02393963
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
Trial: NCT02089061
Drug: BMS-919373
RxNorm normalized name: BMS-919373
DrugBank: BMS-919373 (DB15047)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02089061
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02153944
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg was given orally during study visit
Trial: NCT02153944
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate 20mg was given orally during study visit
Trial: NCT01533246
Drug: linsitinib
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Linsitinib 150mg, twice a day, days 1- 28